WebsiteGear Logo Log In
New User? Sign Up
About | Contact | FAQ
  Home News Web Hosting Domain Name Industry Saturday, December 14, 2019 
Add Press Release News | News Feeds Feeds | Email This News Email


Generics Markets, 2030 - Focus on Value-Added Medicines & Supergenerics
Tuesday, November 19, 2019

DUBLIN, Nov. 11, 2019 /PRNewswire/ -- The "Generics Market: Focus on Value-Added Medicines / Supergenerics, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

In 2018, it was estimated that the availability of low-cost, generic versions of pharmaceutical interventions saved nearly USD 1.6 trillion in healthcare costs in the US over the last decade.

The Generics Market: Focus on Value-added Medicines / Supergenerics, 2019-2030' report features an extensive study of supergenerics, as well as the current landscape and future potential of technology providers that are offering innovative platforms / solutions to supergeneric drug developers.

Given the cost benefits offered, generic medicines usually have high adoption rates. Moreover, upcoming patent expiries of several blockbuster drugs, such as LYRICA, Cialis, Advair and Sensipar, have intensified the interest of several drug manufacturers in the development of generics. As more generic drugs get approved by regulators across the globe, the competition in the industry has steadily increased.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future opportunity within the market. Based on several parameters, such as size of the generic drugs market, share of supergenerics within the generic drugs market and expected annual growth rate across various geographies, we have provided an informed estimate of the likely evolution of the market, in the mid to long term, for the period 2019-2030.

Amongst other elements, the report features:

    --  An overview of recently approved supergenerics (over the period
        2016-2018), featuring information on route of administration, target
        disease indication(s), target therapeutic area(s), approval timeline,
        submission classification code and most active drug developers (in terms
        of number of product approvals). Additionally, it provides a detailed
        assessment of technology providers, offering platforms / solutions for
        supergeneric drug development, including information on year of
        establishment, company size and geographical location.
    --  An informed competitiveness analysis of the technologies captured in our
        database, taking into consideration relevant parameters, such as
        supplier power (based on company size of technology provider) and other
        important technology-related specifications, such as the type of
        molecule, impact on drug properties and route of administration.
    --  Elaborate profiles of prominent technology developers engaged in this
        domain, featuring an overview of the company, its financial information
        (if available), a detailed description of its technology platform(s),
        recent developments and a comprehensive future outlook.
    --  A list of marketed generics that, we believe, are likely to be developed
        as supergenerics in the near future, based on an in-depth analysis
        taking into consideration multiple relevant parameters, such as the
        current annual cost of treatment of the parent drug, year of patent
        expiry, revenues generated in the year before patent expiry, target
        therapeutic area and number of competitor (generic) drugs available in
        the market.
    --  Detailed case studies on five approved supergeneric drugs, including an
        overview of the product along with information on the original / parent
        drug, value proposition offered by the supergeneric version, pricing
        strategies adopted by the developer (if available), annual revenues of
        the supergeneric and parent drug (if available) and the key learnings /
        takeaways from individual case studies.
    --  A discussion on affiliated trends, key drivers and challenges, under a
        comprehensive SWOT framework, featuring a Harvey ball analysis,
        highlighting the relative impact of each SWOT parameter on the overall
        supergenerics industry.

Key Topics Covered:

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Generic Drugs
3.2.1. Key Challenges within the Generics Industry
3.2.1.1. Policy Changes
3.2.1.2. Increasing Competition
3.2.1.3. Price Erosion
3.3. Supergenerics
3.3.1. Techniques Used for the Development of Supergenerics
3.3.2. Regulatory Pathways for Approval of Supergenerics
3.4. Advantages of Supergenerics
3.4.1. Improved Efficacy
3.4.2. Increased IP Protection
3.4.3. Cost and Time Efficient Development Process
3.5. Challenges Related to Supergenerics
3.6. Future Perspectives

4 SUPERGENERIC DRUGS: MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Supergenerics: Overall Market Overview
4.2.1. Analysis by Route of Administration
4.2.2. Analysis by Target Indication
4.2.3. Analysis by Target Therapeutic Area
4.2.4. Analysis by Approval Timeline
4.2.5. Analysis by Submission Classification Code
4.2.6. Analysis by Route of Administration, Target Therapeutic Area and Submission Classification Code
4.2.7. Analysis by Most Active Players

5 TECHNOLOGY PROVIDERS FOR SUPERGENERIC DEVELOPMENT: MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Supergenerics Technology Providers: Overall Market Overview
5.3. Analysis by Type of Drug Modification
5.4. Analysis by Type of Technology
5.5. Analysis by Type of Molecules Formulated / Delivered
5.6. Analysis by Route of Administration
5.7. Analysis by Type of Value Addition
5.8. Analysis by Type of Molecule, Route of Administration and Type of Value Addition
5.9. Analysis by Year of Establishment
5.10. Analysis by Company Size
5.11. Analysis by Geography
5.12 Platform Competitiveness Analysis

6 COMPANY PROFILES: SUPERGENERIC TECHNOLOGY PROVIDERS
6.1. Chapter Overview
6.2. Ascendia Pharmaceuticals
6.2.1. Company Overview
6.2.2. Technology Overview
6.2.2.1. NanoSol
6.2.2.2. AmorSol
6.2.2.3. EmulSol
6.2.3. Recent Developments and Future Outlook
6.3. CritiTech
6.3.1. Company Overview
6.3.2. Technology Overview
6.3.2.1. Spray Drying Technology
6.3.2.2. Supercritical Precipitation Technology
6.3.3. Recent Developments and Future Outlook
6.4. Crossject
6.4.1. Company Overview
6.4.2. Technology Overview
6.4.2.1. ZENEO
6.4.3. Recent Developments and Future Outlook
6.5. DelSiTech
6.5.1. Company Overview
6.5.2. Technology Overview
6.5.2.1. DelSiTech Silica
6.5.3. Recent Developments and Future Outlook
6.6. Heron Therapeutics
6.6.1. Company Overview
6.6.2. Technology Overview
6.6.2.1. Biochronomer
6.6.3. Recent Developments and Future Outlook
6.7. Intellipharmaceutics International
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Technology Overview
6.7.3.1. Hypermatrix
6.7.3.2. nPODDDS
6.7.3.3. PODRAS
6.7.3.4. IntelliFOAM
6.7.3.5. IntelliGITransporter
6.7.3.6. IntelliMatrix
6.7.3.7. IntelliOsmotics
6.7.3.8. IntelliPaste
6.7.3.9. IntelliPellets
6.7.3.10. IntelliShuttle
6.7.4. Recent Developments and Future Outlook
6.8. Kashiv BioSciences
6.8.1. Company Overview
6.8.2. Technology Overview
6.8.2.1. GRANDE
6.8.2.2. KRONOTEC
6.8.2.3. BIOMAXX
6.8.2.4. LOAD
6.8.3. Recent Developments and Future Outlook
6.9. Latitude Pharmaceuticals
6.9.1. Company Overview
6.9.2. Technology Overview
6.9.2.1. Nano-E
6.9.2.2. PG-Depot
6.9.2.3. ARTSS
6.9.2.4. RFAP Matrix
6.9.2.5. RTTS
6.9.2.6. 24H
6.9.2.7. MiniSpheres
6.9.2.8. GelPatch
6.9.3. Recent Developments and Future Outlook
6.10. Mayne Pharma
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Technology Overview
6.10.3.1. SUBA
6.10.3.2. Cleantaste
6.10.3.3. Pellet Technology
6.10.4. Recent Developments and Future Outlooks
6.11. Neurelis
6.11.1. Company Overview
6.11.2. Technology Overview
6.11.2.1. Intravail
6.11.2.2. ProTek
6.11.2.3. Hydrogel
6.11.3. Recent Developments and Future Outlook
6.12. Rubicon Research
6.12.1. Company Overview
6.12.2. Technology Overview
6.12.2.1. RubiERT
6.12.2.2. RubiDT
6.12.2.3. RubiReten
6.12.2.4. RubiSRL
6.12.3. Recent Developments and Future Outlook
6.13. Taiwan Liposome Company
6.13.1. Company Overview
6.13.2. Financial Information
6.13.3. Technology Overview
6.13.3.1. BioSeizer
6.13.3.2. NanoX
6.13.3.3. Polymeric Micelle
6.13.4. Recent Developments and Future Outlook
6.14. tesa Labtec
6.14.1. Company Overview
6.14.2. Technology Overview
6.14.2.1. Transfilm
6.14.2.2. Mucofilm
6.14.2.3. Rapidfilm
6.14.3. Recent Developments and Future Outlook

7 CASE STUDY OF APPROVED SUPERGENERIC DRUGS
7.1. Chapter Overview
7.2. Austedo
7.2.1. Overview
7.2.2. Originator Drug Overview
7.2.3. Value Proposition
7.2.4. Financial Information
7.2.5. Key Learnings
7.3. Abraxane
7.4. Avycaz
7.5. Procysbi
7.6. Trokendi XR

8 LIKELY DRUG CANDIDATES FOR SUPERGENERIC DEVELOPMENT
8.1. Chapter Overview
8.2. Marketed Generic Drugs, 2016-2018
8.2.1. Most Likely Candidates for supergeneric development
8.2.2. Likely Candidates for supergeneric development
8.2.3. Less Likely Candidates for supergeneric development
8.2.4. Least Likely Candidates for supergeneric development

9 SWOT ANALYSIS
9.1. Chapter Overview
9.2. Strengths
9.3. Weakness
9.4. Opportunities
9.5. Threats
9.6. Concluding Remarks

10 MARKET FORECAST

11 CONCLUSION

12 APPENDIX 1: TABULATED DATA

13 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

Companies Mentioned

    --  3M
    --  3SBio
    --  Abon Pharmaceuticals
    --  Abraxis BioScience (a subsidiary of Celgene)
    --  Accord Healthcare
    --  AcelRx Pharmaceuticals
    --  Aclaris Therapeutics
    --  Acorda Therapeutics
    --  Acrotech Biopharma
    --  ACS Dobfar
    --  Actavis (a subsidiary of Teva Pharmaceutical)
    --  Adamis Pharmaceuticals
    --  ADDMEDICA
    --  ADIENNE
    --  Aegis Therapeutics
    --  Ailex Pharmaceuticals
    --  Akorn
    --  Alcon
    --  Alembic Pharmaceuticals
    --  Allergan
    --  ALRISE Biosystems
    --  Altaire Pharmaceuticals
    --  Altus Formulation
    --  Alyvant
    --  American Regent
    --  Amerigen Pharmaceuticals
    --  Amneal Pharmaceuticals
    --  ANI Pharmaceuticals
    --  Antares Pharma
    --  Apotex
    --  Aprecia Pharmaceuticals
    --  Armstrong Pharmaceuticals
    --  Ascendia Pharmaceuticals
    --  Ascendis Pharma
    --  Assertio Therapeutics
    --  AstraZeneca
    --  Aurobindo Pharma
    --  Avadel Pharmaceuticals
    --  Avanir Pharmaceuticals
    --  Avedro
    --  Avion Pharmaceuticals
    --  B. Braun
    --  Bausch & Lomb
    --  Baxter
    --  Bayer
    --  BDD
    --  Belcher Pharmaceuticals
    --  Bharat Serums and Vaccines
    --  BioDelivery Sciences International
    --  Birdie Pharmaceuticals
    --  Bracco
    --  Braeburn
    --  Bristol-Myers Squibb
    --  BWX Technologies
    --  Celator Pharmaceuticals (a subsidiary of Jazz Pharmaceuticals)
    --  Celgene
    --  Cellix Bio
    --  Celltrion Healthcare
    --  Chiesi Farmaceutici
    --  Cintex
    --  Cipla
    --  CMP Pharma
    --  Cocoon Biotech
    --  Coeptis Pharmaceuticals
    --  Covis Pharma
    --  Cristal Therapeutics
    --  CritiTech
    --  Crossject
    --  C-Tri
    --  Cycle Pharmaceuticals
    --  Dauntless Pharmaceuticals
    --  DelNova Healthcare
    --  DelSiTech
    --  Desitin Pharma
    --  Dexcel Pharma
    --  DFB Pharmaceuticals
    --  DisperSol Technologies
    --  Dr. Reddy's Laboratories
    --  Druggability Technologies
    --  EASYWELL BIOMEDICALS
    --  ECI Pharmaceuticals
    --  Edenbridge Pharmaceuticals
    --  ELPEN
    --  Emmaus Life Sciences
    --  Encore Dermatology
    --  EPI Health
    --  epinamics
    --  Eurohealth International
    --  Exela Pharma Sciences
    --  EyePoint Pharmaceuticals
    --  Eyevance Pharmaceuticals
    --  Ferring Pharmaceuticals
    --  Flexion Therapeutics
    --  Foresee Pharmaceuticals
    --  Fresenius Kabi
    --  Galderma
    --  General Atlantic
    --  Genus Lifesciences
    --  Gland Pharma
    --  GlaxoSmithKline
    --  Glenmark Pharmaceuticals
    --  GP Pharm
    --  Handa Pharmaceuticals
    --  Hanmi Pharmaceutical
    --  HANSAmed
    --  HealthCare Royalty Partners
    --  Heron Therapeutics
    --  Hetero
    --  Horizon Therapeutics
    --  Hospira
    --  HQ Speciality Pharma
    --  Hyundai Bioscience
    --  IBSA Institut Biochimique
    --  iCeutica
    --  Impax Laboratories
    --  Impel NeuroPharma
    --  Indivior
    --  InfoRLife
    --  Ingenus Pharmaceuticals
    --  Insmed
    --  INSYS Therapeutics
    --  Intec Pharma
    --  Integral BioSystems
    --  IntelGenx
    --  Intellipharmaceutics International
    --  Intersect ENT
    --  Inventia Healthcare
    --  Ironshore Pharmaceuticals
    --  Italfarmaco
    --  Jiangsu Hengrui Medicine
    --  Jixi Biotechnology
    --  Johnson & Johnson
    --  Jubilant DraxImage
    --  Kala Pharmaceuticals
    --  Kaleo
    --  Kashiv BioSciences
    --  KC Pharmaceuticals
    --  KemPharm
    --  Keystone Nano
    --  KVK Tech
    --  Larken Laboratories
    --  LATITUDE Pharmaceuticals
    --  leon-nanodrugs
    --  LipoSeuticals
    --  Liquidia Technologies
    --  Lundbeck
    --  Lupin
    --  Macleods Pharmaceuticals
    --  Mallinckrodt Pharmaceuticals
    --  Mayne Pharma
    --  Medesis Pharma
    --  MedinCell
    --  Medline Industries
    --  Merck
    --  Meridian Medical Technologies
    --  Micelle BioPharma
    --  Mikart
    --  Mipharm
    --  Mithra Pharmaceuticals
    --  MSN Laboratories
    --  Mylan
    --  Nanocopoeia
    --  NanoVelos
    --  Natco Pharma
    --  NAVINTA
    --  Neos Therapeutics
    --  Nesher Pharmaceuticals
    --  Neurelis
    --  Nexus Pharmaceuticals
    --  Northstar Medical Radioisotopes
    --  Norton (Waterford)
    --  Nostrum Laboratories
    --  NOVADAQ Technologies (a subsidiary of Stryker)
    --  Novatech
    --  Novel Laboratories
    --  Novocol Healthcare
    --  NX Development
    --  Ocular Therapeutix
    --  Opiant Pharmaceuticals
    --  Optinose
    --  Osmotica Pharmaceuticals
    --  Paddock Laboratories
    --  Par Pharmaceutical
    --  Par Sterile Products (a subsidiary of Par Pharmaceutical)
    --  Pearl Therapeutics
    --  Perrigo
    --  Pfizer
    --  Pharmadax
    --  PLx Pharma
    --  Praxair
    --  ProSolus
    --  Provepharm Life Solutions
    --  Raptor Pharmaceuticals
    --  Recordati
    --  Rempex Pharmaceuticals
    --  Rising Pharmaceuticals
    --  Rosemont Pharmaceuticals
    --  Roxane Laboratories (a subsidiary of Hikma Pharmaceuticals)
    --  Rubicon Research
    --  RxMP Therapeutics
    --  Sagent Pharmaceuticals
    --  Salvat
    --  Sandoz
    --  SCILEX Pharmaceuticals
    --  SGN Nanopharma
    --  Shanghai Hengrui Pharmaceutical
    --  Silvergate Pharmaceuticals
    --  Solani Therapeutics
    --  Sol-Gel Technologies
    --  Spear Pharmaceuticals
    --  St. Renatus
    --  Sun Pharmaceutical
    --  Sunny Pharmtech
    --  Sunovion Pharmaceuticals
    --  Supernus Pharmaceuticals
    --  Taiwan Liposome Company
    --  Taro Pharmaceuticals
    --  Teligent
    --  TerSera Therapeutics
    --  tesa Labtec
    --  Teva Pharmaceutical
    --  TherapeuticsMD
    --  Tiger Pharmaceuticals
    --  Titan Pharmaceuticals
    --  Tolmar
    --  Torrent Pharmaceuticals
    --  Tris Pharma
    --  Upsher-Smith Laboratories
    --  US Biotest
    --  Valeant Pharmaceuticals
    --  West-Ward Pharmaceuticals
    --  Xellia
    --  X-GEN Pharmaceuticals
    --  Zydus Cadila

For more information about this report visit https://www.researchandmarkets.com/r/aoqiwd

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/generics-markets-2030---focus-on-value-added-medicines--supergenerics-300955612.html

SOURCE Research and Markets



Email This News Email | Submit To Slashdot Slashdot | Submit To Digg.com Digg | Submit To del.icio.us Del.icio.us | News Feeds Feeds

RELATED NEWS ARTICLES
Nav Worldwide Real Estate: 2019 Annual Report - What's Next for Digital Transactions Online? | Dec 14, 2019
Nav Candid helps to support AWS Outposts | Dec 14, 2019
Nav Dreamersi Web Hosting Now Supports G Suite and Office 365 Email | Dec 14, 2019
Nav Interactive Display Market to Reach $29.20 Bn, Globally, by 2026 at 8.8% CAGR: Allied Market Research | Dec 14, 2019
Nav Cision PR Newswire's Beyond Bylines Blog Featured in Feedspot's List of Top Journalism Blogs | Dec 14, 2019
Nav Subex and RAG Announce First of its Kind Alliance to Leverage Blockchain for Combatting Fraud | Dec 14, 2019
Nav Warburg Pincus and Vivtera Announce Investment in Arise Virtual Solutions | Dec 14, 2019
Nav TCS Positioned as a Leader in Financial Crime and Compliance Operations Services by Everest Group | Dec 14, 2019
Nav Smart Thermostat Market to Reach $8.78 Billion, Globally, by 2026 at 26.0% CAGR, Says Allied Market Research | Dec 14, 2019
Nav Vinfotech advances into a sweeping fantasy sports software development company. | Dec 14, 2019
NEWS SEARCH

FEATURED NEWS | POPULAR NEWS
Submit News | View More News View More News